This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or refuse these technologies

Congratulations on the Successful Listing of Kintor Pharma

2020-05-26

Page View：

On May 22, 2020, Kintor Pharmaceutical Limited (stock code: 9939. HK) was officially listed on the Hong Kong Stock Exchange. We medicilon extend the congratulations and best wishes.

Listing-of-Kintor-Pharma

Medicilon has joined hands with in multiple pharmaceutical development projects in recent years, including external preclinical pharmacokineticstudies and safety evaluation of the androgen receptor antagonist Frestatin (KX-826) and related trials of other drug compounds. The PK and safety evaluation tests of KX-826 completed by Medicilon supports both FDA and NMPA IND filing. In addition, the drug safety evaluation of KX-826 is carried out using mini-pigs as the test species, supporting all stages from preclinical to phases I, II and III clinical trials.

KX-826 -Kintor-Pharma PK-and-safety-evaluation-tests preclinical

Return

Relevant News

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

2019-11-08

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study, DMPK study and the safety evaluation. Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies.

Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform

2022-09-29

Recently, Ringene Biopharma, an innovative drug R&D company focusing on the development of drugs targeting RTK-RAS-MAPK signaling pathway, independently developed a new class of anti-tumor drugs, the irreversible pan-FGFR inhibitor RG002, which was approved clinical. The indications are advanced malignant tumors.

CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform

2022-08-01

On July 22, CGT-9475, a new generation of ALK inhibitor independently developed by CGeneTech (Suzhou, China) Co., Ltd. (CGeneTech), was approved by the US Food and Drug Administration (FDA) to enter the clinical trial.